the industry leader in bioactive lipid-targeted therapeutics, announced that data from the Nexus Phase 2 study of iSONEP™ will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on Saturday, November 14 at 12:59 p.m. Pacific Time. Presenting the data in an oral presentation will be Thomas Ciulla, M.D., a Nexus investigator and practicing ophthalmologist and retinal surgeon in Indianapolis, IN.
In May, Lpath announced that iSONEP did not meet the primary or key secondary endpoints in the Nexus trial, a prospective, randomized, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet age-related macular degeneration (wet AMD) who had been subresponsive to treatment with existing anti-vascular endothelial growth factor (VEGF) therapies. Nexus trial patients did not show any statistically significant improvement in visual acuity at day 120 when treated with iSONEP as an adjunctive or monotherapy. Lpath conducted further analyses of the data including additional anatomical endpoints to better understand the results from each arm of the trial, and those findings will be included in the presentation at the AAO Annual Meeting. The presentation slides will be made available on Lpath's website (www.lpath.com) following the meeting and the company also plans to host a conference call on Tuesday, November 17, 2015 at 2:00 p.m. Pacific Time to discuss the additional findings. Details for the conference call will be announced on Monday, November 16, 2015.
News 
Market Data 
Discover 
